Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer

Inclusion Criteria

• •1. Patients with diagnosis of epithelial ovarian carcinoma, peritoneal carcinoma, or fallopian tube carcinoma within 3 lines recurrence;
• •2. Recurrence occurred within 6 months since platinum-based chemotherapy;
• •3. R0 ideal debulking in initial surgery; PET-CT indicate the recurrence lesion is almost in abdominal cavity, which is isolated and not exceed 5 sites, and the ascites is less than 500ml;
• •4. ECOG/WHO Performance score of 0 to 1;
• •5. Hematology function: Leukocyte≥ 3,5x10⁹/L, neutrophil≥ 1,5x10⁹/L, platelets ≥ 100x10⁹/L;
• •6. No Renal insufficiency: serum creatinine \< 1,5 time the normal limit, creatinine clearance \> 60 mL/min;
• •7. No hepatic failure: bilirubin ≤ 1,5 time the Normal limit;
• •8. Patients with good compliance;
• •9. Patients having read, signed and dated Informed consent before any study procedure.